Introduction {#S1}
============

The *Herpesviridae* is a family of large, structurally complex viruses with double-stranded DNA genomes. This family is classified into three subfamilies according to biological and genomic similarities: *alphaherpesvirinae*, *betaherpesvirinae*, and *gammaherpesvirinae* ([@B57]). Several viruses with significant medical relevance are represented in this family, which cause a series of maladies ranging from cold sores or fever blisters to a variety of human cancers. A distinctive feature of herpesviruses is their ability to establish lifelong latent infections, with infected individuals serving as reservoirs from which period reactivation leads to continual and anew transmission to naive hosts.

Herpesviruses are known for the impressive toolbox they have evolved to circumvent the host's immune response. Throughout the lifelong coexistence with their hosts, herpesviruses antagonise the immune response at every level: the signalling pathways downstream of pattern recognition receptors (PRR) (reviewed in [@B45]; [@B66]) and the IFNα/β receptor (IFNAR) ([@B84]), Natural Killer cell responses (reviewed in [@B15]), the complement system (reviewed in [@B67]) and the adaptive immune response (reviewed in [@B65]). However, our understanding of the interplay between herpesviruses and the interferon-stimulated gene (ISG) network is only in its infancy. So far, more than 380 human ISGs, with their functions ranging from sensors, cytokines or transcription factors, to proapoptotic proteins or negative regulators, have been tested for their ability to inhibit the replication of a panel of RNA viruses, revealing that different viruses are targeted by unique sets of ISGs ([@B63]). Such a screen has not been performed for the different members of the *Herpesviridae*, however, recent studies have identified multiple herpesviral antagonists which target ISGs, showcasing the importance of ISGs in combating herpesviral infection.

In this review, we will discuss the current knowledge regarding the complex interaction between ISGs and human herpesviruses and highlight how each subfamily of human herpesviruses has evolved unique mechanisms to counteract ISGs or, in some cases, even exploit ISGs to the advantage of the virus ([Figure 1](#F1){ref-type="fig"}).

![Herpesviruses use a variety of strategies to manipulate ISGs. Viral proteins can interfere with protein expression and stability of ISGs, inhibit signalling pathways exerted by ISGs or, in some cases, exploit ISGs for their own benefit. Viral proteins are depicted in red, while ISGs are shown in green. Abbreviations: HSV-1, herpes simplex virus type 1; HCMV, human cytomegalovirus; KSHV, Kaposi's sarcoma-associated herpesvirus; IFI16, gamma-interferon-inducible protein 16; STING, stimulator of interferon genes; IFN, interferon; ZAP, zinc finger CCCH-type antiviral protein; IFIT3, interferon-induced protein with tetratricopeptide repeats 3; NMI, N-myc-interactor; STAT1/2, signal transducer and activator of transcription 1/2; ISG15, interferon-stimulated gene 15; IRF, interferon regulatory factor; OASL, 2′-5′-Oligoadenylate synthetase like; OAS1, 2′-5′-Oligoadenylate synthetase 1; RNase L, ribonuclease L.](fmicb-11-00124-g001){#F1}

How It All Starts: ISGs Enter the Game {#S2}
======================================

The DNA sensing pathway mediated by the PRR cyclic GMP-AMP synthase (cGAS) and gamma-interferon-inducible protein 16 (IFI16) is crucial for the initial immune response to herpesviral infection in many cell types ([@B2]; [@B42]; [@B78]; [@B56]). The DNA sensors cGAS and IFI16 bind to viral and aberrantly localised cellular DNA. This interaction activates a signalling cascade through the adaptor protein stimulator of interferon genes (STING) and TANK-binding kinase 1 (TBK1), thereby activating the transcription factors interferon regulatory factor 3 (IRF3) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) (reviewed in [@B9]). This leads to the induction of type I interferons (IFN), which exert their activity in an autocrine and paracrine manner. By binding to the interferon-α/β receptor (IFNAR), these cytokines lead to phosphorylation and activation of the transcription factors signal transducers and activators of transcription, STAT1 and STAT2, recruiting IRF9 into the complex which then translocates to the nucleus, resulting in ISG expression (reviewed in [@B60]). Another class of ISGs, known as non-canonical ISGs, are activated directly by IRF3 in the absence of type I IFN ([@B62]). For a third class of proteins classified as ISGs, the presence of IRF3 or type I IFN is not an absolute prerequisite for their expression, since they are already expressed basally or their expression is induced by other pathways, i.e., NF-κB signalling (reviewed in [@B61]). Thus, due to this complexity and the wide range of functions that ISGs can exert, studying how herpesviruses manipulate ISGs to their advantage serves as a window into a greater understanding of the myriad of ISGs and their role in innate immunity. Similar to the studies on ISGs and RNA viruses ([@B63]), studies identifying how herpesviruses inhibit or exploit the function of ISGs may reveal the essential nature of the role these ISGs play in viral defence.

When Herpesviruses Win: Escaping the Antiviral Effects of ISGs {#S3}
==============================================================

Herpes Simplex Virus 1 {#S3.SS1}
----------------------

Herpes simplex virus 1 (HSV-1) belongs to the *Alphaherpesvirinae* subfamily. HSV-1 establishes a primary infection in mucosal epithelia and a latent infection in the ganglia of sensory nerves. This infection, as in the case of all herpesviruses, can be asymptomatic, but it may also present as acute gingivostomatitis. Furthermore, HSV-1 can lead to serious illnesses like ophthalmic infections, meningitis or encephalitis ([@B57]). Recently, HSV-1 has also been associated as a major risk factor for Alzheimer's disease ([@B28]).

### Targeting DNA Sensing: ICP0 Degrades the ISG IFI16 {#S3.SS1.SSS1}

Herpesviruses replicate in the nucleus of their host cells. The ISG IFI16 is a cellular DNA sensor localized in the nucleus of many cell types ([@B74]; [@B18]; [@B75]; [@B35]). [@B54] demonstrated that HSV-1 targets the IFI16 protein. During infection, when HSV-1 expresses the immediate-early viral protein ICP0 in the nucleus of human foreskin fibroblasts (HFF), IFI16 undergoes a change in its location and is continuously degraded. However, another study found that the expression of ICP0 alone is neither sufficient nor necessary for degradation of IFI16 in the tumor-derived cell line U-2 OS, since infection with an ICP0-null mutant still resulted in IFI16 degradation ([@B13]). A follow-up study by [@B53] clarified this discrepancy by showing that IFI16 protein levels decrease upon HSV-1 infection in HFF, keratinocytes (NOK), and HeLa cells, but not in the U-2 OS cell line, and additionally discovered that ICP0 is not the only protein involved in IFI16 degradation ([Table 1](#T1){ref-type="table"}). This suggests that the role of ICP0 for IFI16 degradation is dependent on the cell type and other cellular or viral factors contributing to IFI16 stability ([@B37]).

###### 

Viral antagonists of interferon-stimulated genes (ISGs).

  **Virus**   **Strain**                        **Viral antagonist**   **Target ISG**   **Cell type**                        **Viral evasion strategy**                                                                                                                                                      **References**
  ----------- --------------------------------- ---------------------- ---------------- ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  **HSV-1**   KOS                               ICP0                   IFI16            HFF                                  Degrades IFI16                                                                                                                                                                  [@B54]
              17+                               ICP0                   IFI16            U-2 OS                               Does not degrade IFI16                                                                                                                                                          [@B13]
              KOS, 17, F                        UL41 (vhs)             IFI16            HFF NOK, HeLa, U-2 OS                ICP0 degrades IFI16 in a cell-type specific manner; UL41 also reduces protein levels of IFI16 (presumably by RNA degradation)                                                   [@B53]
              F                                 UL41                   ZAP              293Trex-hZAPL/S                      Degrades ZAP mRNA through its endoribonuclease activity, preferentially binds ARE motifs                                                                                        [@B69]
              F                                 UL41                   IFIT3            293T                                 Decreases IFIT3 expression levels by degrading IFIT3 mRNA, does not target IFIT1 or IFIT2                                                                                       [@B34]
  **HCMV**    AD169                             UL83 (pp65)            IFI16            HFF                                  Interacts with IFI16 to block its oligomerisation and prevents signalling; promotes transcription of immediate early genes by exploiting the binding capacity of IFI16 to DNA   [@B42]
              TB40/E                                                                                                                                                                                                                                                                                         [@B6]
              AD169                                                                                                                                                                                                                                                                                          [@B12]
              Towne (BAC-derived)               UL23                   NMI              U251                                 Inhibits ISG transcription by binding to NMI and disrupting its association with STAT1                                                                                          [@B21]
              Towne                             IE1 (UL123)            ISG15            HF                                   Inhibits HCMV-induced ISG15 expression and thereby prevents ISGylation                                                                                                          [@B38]
              AD169                             UL26                   ISG15            HF                                   Reduces the accumulation of ISGylated proteins by acting as a decoy target for ISG15                                                                                            [@B38]
              Towne                             ORF94 (UL126a)         OAS1             HF                                   Inhibits mRNA and protein expression of OAS1, leading to reduced viral RNA degradation                                                                                          [@B72]
  **KSHV**    iSLK.219 harbouring rKSHV.219\*   vIRF1                  ISG15            293, 293-TLR, BCBL PEL, iSLK.219     Reduces ISGylation of cellular target proteins, leading to IRF3 instability and decreased ISG transcription; acts as a decoy target for ISG15                                   [@B31]
              HuARLT2 harbouring rKSHV.219\*    ORF20                  OASL             293T, HeLa, HFF, HuARLT2-rKSHV.219   ORF20 and OASL interact; ORF20 increases RIG-I dependent OASL expression; OASL and ORF20 concomitantly enhance KSHV infection                                                   [@B7]

\*These studies used iSLK or HuARLT2 cells that were latently infected with recombinant rKSHV.219 (

Vieira and O'Hearn, 2004

;

Myoung and Ganem, 2011

;

Lipps et al., 2017

). HFF, human foreskin fibroblasts; HF, human fibroblasts.

### Degrading ISG mRNA: UL41 Counteracts ZAP and IFIT3 {#S3.SS1.SSS2}

The HSV-1 tegument protein UL41, also known as virion host shutoff (vhs) protein, is an endoribonuclease that degrades mRNA ([@B20]; [@B55]). It is proposed that viral and cellular mRNAs containing AU-rich elements (ARE) in the 3′-untranslated region (3′-UTR) are the preferred target for UL41 ([@B19]; [@B70]). Since ARE regions are frequently present in transcripts connected to the immune response, including interferons and chemokines ([@B4]), UL41 could potentially target a broad spectrum of transcripts. To date, the zinc finger CCCH-type antiviral protein 1 (ZAP) and the ISG interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) are two ISGs that contain ARE in their 3′-UTR which have been shown to be incapacitated by UL41 ([Figure 1](#F1){ref-type="fig"}).

The zinc finger CCCH-type antiviral protein is a non-canonical ISG ([@B62]), meaning that its expression can also be induced in the absence of type I IFN production. ZAP exerts antiviral activity against a diverse range of viruses such as retroviruses, alphaviruses, filoviruses, hepatitis B virus and Japanese encephalitis virus by binding to RNA and indirectly mediating its degradation ([@B5]; [@B51]; [@B83]; [@B47]; [@B71]; [@B11]). However, ZAP fails to control other viruses, e.g., influenza A virus ([@B44]; [@B73]) or enterovirus A71 ([@B79]).

In the case of HSV-1, ectopic expression of both rat and human forms of ZAP does not affect HSV-1 infection ([@B5]), which suggested that a viral antagonist may counteract the antiviral activity of ZAP. Accordingly, a luciferase-based assay in 293T cells identified the HSV-1 UL41 protein as a ZAP antagonist ([@B69]). In accordance with previous observations regarding the nuclease activity of UL41, this viral protein was shown to degrade ZAP mRNA during HSV-1 infection. Correspondingly, growth of a mutant virus lacking UL41 expression was impaired in the presence of ZAP ([@B69]).

Similarly, IFIT3 was reported to have no effect on HSV-1 infection ([@B34]). As for ZAP, human IFIT proteins with the family members IFIT1, IFIT2, and IFIT3 belong to the subgroup of non-canonical ISGs ([@B62]). IFIT3 mediates the association of TBK1 with mitochondrial antiviral-signalling protein (MAVS) at the mitochondria ([@B46]), enhancing the MAVS-TBK1 signalling axis. Notably, IFIT3 inhibits the replication of HSV-1 lacking UL41 expression, underlining the importance of UL41 in evading the antiviral effect of IFIT3. The authors showed that UL41 degrades IFIT3 mRNA, but not that of IFIT1 or IFIT2 ([@B34]), indicating that HSV-1 may specifically target IFIT3 to prevent the MAVS-TBK1 association, thus suppressing downstream signalling.

Human Cytomegalovirus {#S3.SS2}
---------------------

Human cytomegalovirus (HCMV), also called human herpesvirus 5 (HHV-5), is a member of the *Betaherpesvirinae* subfamily. HCMV usually causes only mild disease in immunocompetent individuals. However, in immunosuppressed individuals such as AIDS or transplant patients, HCMV infection can cause severe complications (reviewed in [@B3]). HCMV infection during pregnancy can cause long-term sequelae in newborns, such as hearing loss, vision abnormalities, microcephaly or global development delays.

### Targeting DNA Sensing: UL83 Hijacks the ISG IFI16 {#S3.SS2.SSS1}

Human cytomegalovirus, as for HSV-1, interferes with DNA sensing by targeting IFI16 via the UL83 encoded tegument protein pp65. Upon HCMV infection, IFI16 is activated in the nucleus and undergoes oligomerisation, which is a prerequisite for it to promote the immune response ([@B12]; [@B42]). Accordingly, siRNA-mediated silencing of IFI16 dampens cytokine transcription in response to HCMV infection ([@B42]). However, UL83 prevents IFI16 oligomerisation, thus disarming the antiviral effect of IFI16 during HCMV infection ([@B42]). UL83 even goes a step further in its manipulation of host responses: it exploits the binding capacity of IFI16 to DNA in order to form a complex with the major immediate early promoter (MIEP) of HCMV, thereby triggering viral transcription in the early stages of infection ([@B12]; [@B6]). In this manner, UL83 not only prevents the antiviral activity of IFI16 but also hijacks it to promote HCMV gene expression ([Figure 1](#F1){ref-type="fig"}). This viral protein serves as a stellar example of the resourcefulness of herpesviruses in encoding a protein that can simultaneously inhibit a host antiviral strategy while exploiting this same host response factor to promote its own replication.

### Fooling the Type I IFN Response: UL23 Inhibits ISG Transcription by Targeting the ISG NMI {#S3.SS2.SSS2}

The ISG N-myc interactor (NMI) interacts with all STATs, except STAT2, and enhances the recruitment of co-activators, such as the transcription factors CREB-binding protein (CBP)/p300, to the STAT complex. NMI specifically modulates IFN-induced signalling to foster efficient STAT-dependent transcription ([@B82]). Recently, the HCMV tegument protein UL23 was reported to inhibit the transcription of ISGs by targeting NMI. Through a yeast two-hybrid screen, NMI was identified as an interacting partner of UL23, which was confirmed by co-immunoprecipitation in HCMV-infected U251 cells ([@B21]). Using a combination of immunofluorescence, cell fractionation and immunoblotting, the authors showed that the binding of UL23 to NMI disrupts its association with STAT1, thereby preventing the translocation of both proteins to the nucleus ([Figure 1](#F1){ref-type="fig"}). Infection of U251 cells with an HCMV UL23-null mutant resulted in enhanced transcription of antiviral genes and controlled viral replication.

### HCMV Finds Ways to Avoid ISGylation: Both IE1 and UL26 Target ISG15 {#S3.SS2.SSS3}

Interferon-stimulated gene 15 (ISG15) encodes an ubiquitin-like protein that, in a similar way to ubiquitin, covalently conjugates to lysine residues, thereby regulating protein function (reviewed in [@B33]). ISG15 modification is known as ISGylation, which marks proteins for either degradation or stabilisation. ISG15 is one of the most abundantly produced transcripts upon induction of the type I IFN response ([@B17]; [@B58]) and exerts antiviral effects against DNA and RNA viruses ([@B40]; [@B50]).

Human cytomegalovirus infection induces ISG15 expression, which, through ISGylation, inhibits viral replication ([@B38]). HCMV employs two proteins with two separate strategies to evade this process ([Figure 1](#F1){ref-type="fig"}). First, the viral immediate-early protein IE1 suppresses ISG15 transcription ([@B38]). However, this effect is only partial, and therefore some ISG15 protein is still expressed to carry out ISGylation, which is protected from the antagonistic activity of IE1. To counteract this remnant ISG15, HCMV expresses the tegument protein UL26, which reduces the accumulation of other viral ISGylated proteins by acting as a decoy for ISGylation itself ([@B38]). UL26 is known as an antagonist of the NF-κB pathway ([@B49]), but ISGylated UL26 can no longer antagonise NF-κB signalling ([@B38]), suggesting that the virus sacrifices one of its own proteins to avoid ISGylation of other viral proteins. Why UL26 is more prone to ISGylation compared to other viral proteins, and the impact of the loss of its effect on NF-κB signalling during HCMV infection remains unclear at this stage. This in turn raises the question of whether the dominant role of UL26 is to inhibit NF-κB signalling or to act as an ISGylation decoy, since these seem to be opposing functions.

### Targeting an Essential Player of the Innate Immune Response: ORF94 Against the ISG OAS1 {#S3.SS2.SSS4}

Human cytomegalovirus expresses several genes during latency to avoid immune recognition of infected cells ([@B32]; [@B10]), the so-called CMV latency-associated transcripts (CLTs). These products are also expressed during lytic HCMV infection. HCMV ORF94 (also known as UL126a) is one such transcript, and its localization in the nucleus suggests a potential role in cellular gene regulation ([@B77]). ORF94 was shown to inhibit both the transcription and translation of the ISG 2′-5′-oligoadenylate synthetase 1 (OAS1) ([@B72]). OAS1, together with OAS2, OAS3, OAS-like (OASL), and cGAS, forms the OAS family ([@B36]). Upon detection of double stranded RNA (dsRNA), OAS1-3 proteins are activated and oligomerise ATP into 2′,5′-linked oligoadenylate products (2-5A). This leads to the activation of endoribonuclease L (RNase L), which in turn degrades viral and cellular RNA. Thus, expression of HCMV ORF94 reduces OAS mRNA and protein levels and consequently the formation of 2-5A during productive infection in human fibroblasts ([Figure 1](#F1){ref-type="fig"}; [@B72]). However, as ORF94 is expressed in both the productive and latent phases of HCMV infection, it could potentially contribute to latency by modulating the immune response, which would be an intriguing avenue of further research.

Kaposi's Sarcoma-Associated Herpesvirus {#S3.SS3}
---------------------------------------

Kaposi's sarcoma-associated herpesvirus (KSHV), also called human herpesvirus 8 (HHV-8), belongs to the *Gammaherpesvirinae* subfamily. KSHV is one of the seven known human oncoviruses. It can cause multiple malignancies, namely Kaposi's sarcoma, primary effusion lymphoma, multicentric Castleman's disease, or KSHV inflammatory cytokine syndrome ([@B8]; [@B1]; [@B22]).

### Targeting ISGylation: vIRF1 and ISG15 {#S3.SS3.SSS1}

Kaposi's sarcoma-associated herpesvirus encodes four viral homologs of cellular interferon regulatory factors (vIRFs) ([@B29]). In 2013, [@B30] showed that vIRF1 inhibits the type I IFN response. By performing affinity purification coupled to mass spectrometry with cells expressing vIRF1 and in which TLR3 signalling was activated, the authors identified the cellular ISG15 E3 ligase, HERC5, as an interaction partner of vIRF1 ([@B31]). HERC5 interacts with the C-terminus of vIRF1. Moreover, vIRF1 reduces total ISG15 conjugation levels on cellular target proteins, which in turn inhibits IRF3 function as it relies on ISGylation for stabilisation ([Figure 1](#F1){ref-type="fig"}; [@B64]). Additionally, siRNA-mediated knockdown of ISG15 or HERC5 increases KSHV replication upon reactivation. Therefore, it is possible that vIRF1 negatively regulates ISGylation by interacting with HERC5, leading to a decrease in IRF3 stability and reduced transcription of ISGs. Interestingly, the authors observed by immunoprecipitation that vIRF1 is conjugated to ISG15 at multiple sites, suggesting a role as a viral ISGylation target similar to the HCMV protein UL26 ([@B38]), which may reflect a conservation of this function between herpesvirus subfamilies.

While KSHV vIRFs inhibit IFN signalling, type I IFN is not always detrimental for herpesviruses as it plays an important role for the maintenance of latency ([@B80]; [@B16]; [@B14]; [@B25]). In line with these findings, vIRF2 has been recently described to manipulate the innate immune response. vIRF2 regulates the expression of 51 genes known to be involved in innate or intrinsic defences, boosting the formation of the antiviral cellular state to restrict KSHV early lytic protein expression and promote latency ([@B39]). This is an intriguing illustration of the fine-tuned balance between herpesviruses and their host, which dictates the outcome of the infection course.

### Profiting From ISGs: ORF20 Fancies the ISG OASL {#S3.SS3.SSS2}

The OAS family member OASL shares a highly conserved N-terminal OAS-like domain with the OAS enzymes, but it lacks enzymatic activity and has a unique C-terminus composed of two ubiquitin-like domains ([@B24]). In addition, OASL binds dsRNA ([@B27]). OASL was identified as an ISG with targeted, but not broad antiviral specificity against a variety of RNA viruses ([@B63], [@B62]). Its role for HSV-1 is more controversial - while one study observed no role for OASL on HSV-1 replication ([@B48]), another reported that OASL inhibited HSV-1 ([@B81]).

We showed that the KSHV protein ORF20 interacts with OASL, presumably in the nucleoli given their subcellular localization ([@B7]). Interestingly, stable expression of OASL enhances KSHV replication in an ORF20-dependent manner ([Figure 1](#F1){ref-type="fig"}). Since both proteins interact with ribosomal proteins and co-sediment with ribosomal subunits, which are involved in the formation of active ribosomal complexes, ORF20 may manipulate OASL so that KSHV can seize control of the host translational machinery. However, further studies are needed to understand the mechanism by which KSHV ORF20 usurps OASL. It is worth noting that the expression of ORF20 in 293T cells specifically enhances OASL mRNA and protein levels. This may be congruent with the observation of a recent study that OASL negatively affects the DNA-binding ability of the DNA sensor cGAS ([@B23]), which is a crucial sensor of KSHV infection ([@B78]). Thus, enhanced levels of OASL during lytic KSHV replication may inhibit cGAS-mediated activation of the innate immune response and therefore provide a more conducive environment for infection.

Final Remarks {#S4}
=============

The complex interaction between herpesviruses and their host is essential for the outcome of infection. In the case of ISGs, understanding the mechanisms by which herpesviruses manipulate these effectors gives an insight into both how viruses establish lifelong infections and the role that ISGs play in immune defence. The importance of ISGs for antiviral defence is indisputable, given that IFNAR knockout mice readily succumb to infection with herpesviruses ([@B68]; [@B41]; [@B59]). Interestingly, several studies reported only minor defects in mice lacking individual ISGs ([@B41]), supporting the notion that at least some ISGs may act in concert to exert their full effect, or the existence of ISGs with redundant functions. Moreover, a recent study revealed the complex network that ISGs create during viral infection, not just by binding to other ISGs, but also to many other cellular proteins ([@B26]), adding an even greater level of complexity to the host immune response against infection.

We have only just crossed the starting line to understanding whether certain ISGs are proviral or antiviral in the context of herpesviral infections. This investigation into the role and mechanism of action of ISGs is challenging. Overexpression studies may give some valuable insights into the function of these ISGs. However, since viral infections induce the expression of multiple ISGs that may cooperate, studies on a single ISG may not reflect reality or at least may not reveal the full potential of the individual ISG tested. Ideally, tagged, endogenously expressed ISGs would be used for co-immunoprecipitation studies in infected cells to identify viral and/or cellular binding partners of them. To expand on these studies, analysis of single and combined ISG knockouts will help to determine whether ISGs have a proviral role, an antiviral role, or neither. Another point to consider is that some ISGs may have diverse functions in different cell types while other ISGs may be species-specific.

Herpesviruses are a very valuable tool in the endeavour to uncover the role that ISGs play in antiviral defence as they are highly adapted and have likely developed multiple antagonists ([Table 1](#T1){ref-type="table"}). However, viral antagonists can be friend or foe: while the function of ISGs may only be revealed in the absence of viral antagonists, these opponents may be key to our greater understanding of how cellular defence is regulated. Through our bid to decipher the intricacies of this complex interplay between herpesviruses and the tailored ISG response to individual infections, we may uncover novel targeted therapies against these masters of immune escape and manipulation.
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